Â
Latest Cardiac Valve Companies Update
Edwards Lifesciences' TAVR Melodyâ„¢ 34 Valve: In October 2023, Edwards Lifesciences received FDA approval for its TAVR Melodyâ„¢ 34 valve, the first transcatheter aortic valve replacement (TAVR) device specifically designed for patients with smaller aortic annuli. This expands treatment options for a previously underserved patient population.
Abbott's Porticoâ„¢ Transcatheter Mitral Valve System: In November 2023, Abbott announced the initiation of a pivotal US clinical trial for its Porticoâ„¢ Transcatheter Mitral Valve System, a less invasive treatment option for mitral valve regurgitation. Positive results could significantly impact the market landscape.
Medtronic's Harmonyâ„¢ Transcatheter Valve System: Medtronic is pursuing FDA approval for its Harmonyâ„¢ Transcatheter Valve System, a next-generation TAVR device featuring a repositionable and retrievable design for enhanced procedural control and safety.
List of Cardiac Valve Key Companies in the Market
- Medtronic
- Edwards Lifesciences Corporation
- Boston Scientific Corporation
- LivaNova PLC
- Abbott
- CryoLife, Inc
- On-X Life Technologies, Inc.
- Colibri Heart Valve
- JenaValve Technology, Inc.
- TTK HealthCare